Compare CURI & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURI | DERM |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.0M | 190.3M |
| IPO Year | 2019 | 2021 |
| Metric | CURI | DERM |
|---|---|---|
| Price | $2.61 | $7.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $5.83 | ★ $12.67 |
| AVG Volume (30 Days) | ★ 2.0M | 179.4K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 10.36% | N/A |
| EPS Growth | ★ 54.17 | 34.72 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $78,043,000.00 | $61,858,000.00 |
| Revenue This Year | $14.91 | $39.72 |
| Revenue Next Year | $12.91 | $63.24 |
| P/E Ratio | $22.08 | ★ N/A |
| Revenue Growth | 9.52 | ★ 10.20 |
| 52 Week Low | $2.30 | $4.31 |
| 52 Week High | $5.51 | $9.56 |
| Indicator | CURI | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 44.93 | 54.69 |
| Support Level | $2.51 | $7.25 |
| Resistance Level | $2.95 | $8.29 |
| Average True Range (ATR) | 0.15 | 0.40 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 17.92 | 51.11 |
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. The firm's products and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, and Others. The majority of the revenue comes from the direct business and Content licensing. Geographically, the company generates the majority of its revenue from the United States.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.